

September 22, 2017

Cancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th

RUTHERFORD, N.J., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (the Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced it will be presenting at this year's Disruptive Growth Company Showcase on September 27th in New York City.

John A. (Jay) Roberts, Chief Operating Officer and EVP, Finance of CGI, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

2017 Disruptive Growth Company Showcase NYC – Cancer Genetics, Inc. Presentation

Date: Wednesday, September 27, 2017
Time: 1:30 pm Eastern Time
Location: Grand Hyatt New York
Webcast: <http://www.investorcalendar.com/event/20311>

ABOUT CANCER GENETICS

Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India, China and Australia. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

Internet: www.cancergenetics.com
Twitter: [@CancerGenetics](https://twitter.com/CancerGenetics)
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects

expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:

Laurie Little
The Piacente Group, Inc.
1-212-481-2050
ir@cgix.com



Source: Cancer Genetics, Inc.